BARDA Expands US Domestic Production Of Single-Use Systems For Vaccine Manufacturing
FlexBiosys wins award; others to follow. New capacity may also benefit manufacture of monoclonal antibodies and cell and gene therapies.
You may also be interested in...
US FDA is looking at risk-based approach for reporting changes in out-of-stock components such as plastic bioreactor bags, filters and tubing sets that are in short supply.
BARDA and Development Financing Corp. officials provide insights into window of opportunity for partnering on manufacturing scale-up.
Distress grows as manufacturers wait for suppliers to boost production. One idea: stretch inventories by qualifying single-use bioreactors for reuse.